<DOC>
	<DOCNO>NCT01621243</DOCNO>
	<brief_summary>People primary metastatic pancreatic cancer treat nab-paclitaxel gemcitabine combination investigational agent call necuparanib ( M402 ) . It make heparin , well know blood thinner . Blood thinner show prior animal human study anti-cancer effect . Necuparanib re-engineered heparin much low blood thin activity keep anti-tumor activity . The investigator test whether necuparanib administer combination nab-paclitaxel gemcitabine may effective nab-paclitaxel gemcitabine .</brief_summary>
	<brief_title>M402 Combination With Nab-Paclitaxel Gemcitabine Pancreatic Cancer</brief_title>
	<detailed_description>Part A open-label , multiple ascend dose patient study necuparanib give first single dose daily combination nab-paclitaxel gemcitabine regimen . It conduct evaluate safety tolerability necuparanib alone combination nab-paclitaxel gemcitabine recommend necuparanib dose regimen subsequent evaluation Part B . Part B randomize , double-blind study investigate antitumor activity necuparanib combination nab-paclitaxel gemcitabine compare nab-paclitaxel , gemcitabine , placebo . In Parts A B , treatment period consist one 28-day cycle . The Study Patient Investigator decide continue additional 28-day cycle accord patient 's status end 28-day cycle . Part A complete enrollment Part B currently open . Part A - Primary Objectives : - To evaluate safety tolerability necuparanib combination nab-paclitaxel gemcitabine . - To determine dose necuparanib carry forward Part B . Part B - Primary Objective : To evaluate overall survival patient treat necuparanib + nab-paclitaxel + gemcitabine compare placebo + nab-paclitaxel + gemcitabine .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Age 18 year old Confirmed pancreatic ductal adenocarcinoma Metastatic disease document CT scan MRI ( locally advance disease NOT eligible ) At least 1 site disease measurable RECIST ver1.1 ECOG performance status 0 1 Adequate bone marrow , renal capacity hepatic function Willing administer daily subcutaneous injection home Any prior radiotherapy , chemotherapy , surgery , investigational therapy adjuvant metastatic pancreatic cancer History suspect history , presence heparin induce toxicity ( w/ w/o thrombosis ) History unexplained bleeding episode within 3 month M402 dose Received thrombolytic agent w/in previous month Had fulldose anticoagulation heparin , enoxaparin , dalteparin , LMWH , a/or anticoagulant w/in 90 day first dose M402 High cardiovascular risk , include limited , recent coronary stenting myocardial infarction past year Major trauma surgery w/in prior 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>necuparanib</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>heparin</keyword>
	<keyword>low molecular weight heparin</keyword>
	<keyword>nab-Paclitaxel</keyword>
</DOC>